Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10599696		
Filing Date		2006-10-05		
First Named Inventor Marc		Gibson-Collinson		
Art Unit				
Examiner Name				
Attamen Dealest Numb		MCC 0404 DUCA		

				,	J.J. I	AILHIO				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	•	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines w nt Passages or R s Appear	
	1	5253434		1993-10-19	,	Reebok Int				
	2	5499459		1996-03-19	,	Brown Shoe C	0			
	3	5855079		1999-01-05	,	Meling Nina				
	4	6311412		2001-11-06		Morning Pride	Manufacturing			
If you wis	h to a	dd additional U.S. Pater	nt citatio	n informatic	on pl	ease click the	Add button.		Add	
			U.S.P	ATENT AP	PLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	n	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines w nt Passages or R s Appear	
	1									
If you wis	h to a	dd additional U.S. Publi:		<u>.                                      </u>				d button		
				FOREIGN	PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		nd ode4	Publication Date	Name of Patente Applicant of cited	e or	Pages,Columns,Li where Relevant Passages or Rele Figures Appear	т-

U.S.PATENTS

# Application Number 10596966 | Filing Date 12006-10-05 | Filing Date 2006-10-05 | Filing Date 200

	1	2408190		GB	A	2005-05-25	Polyformes Limited UK		
If you wis	h to a	dd additio	nal Foreign F	atent Document	citation	information p	lease click the Add butto	n Add	
				NON-PATE	NT LITI	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journat, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Тs	
	1								
If you wis	h to a	dd additio	nal non-pater	nt literature docu	ment ci	tation informat	ion please click the Add	button Add	
				E)	CAMINE	R SIGNATUR	E		
Examiner	Signa	ature					Date Considered		
*EXAMIN	ER: Ir	nitial if ref	erence consid	lered, whether o	r not cit	ation is in conf	ormance with MPEP 609	. Draw line through a	

See York Code of USPTO Pears Documents at your USPTO\_DQV or MEEP 901.04. Totals often that issued the document, by the locations code (IPPO Secretary 5.3). The parease parted counters() are obtained or they ward for a larger price to be useful annuated or the parted for support and the parted or the parted for parted.

York of document by the appropriate symbols as indicated on the document under WIPO Standard 57.16 if possible. Sppticant is to place a check mark there if English spacings entertaints in a standard.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10599696
Filing Date		2006-10-05
First Named Inventor Marc		Gibson-Collinson
Art Unit		
Examiner Name		
Attorney Docket Number		MGC 0101 PUSA

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(40).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

▼ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

on de signature.								
Signature	/John E. Nemazi/	Date (YYYY-MM-DD)	2007-05-16					
Name/Print	John F. Nemazi	Registration Number	30.876					

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiler. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.